GlassScriptPhysician profile
Shajadi Patan
NPI 1073921169
$7,982.34
in general payments reported to CMS, 2019-2025
70 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $214 · 2021: $627 · 2022: $1,356 · 2023: $2,500 · 2024: $715 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,847.07 |
| Education | $395.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $593.70 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $591.62 | 2020-2025 | |
| Janssen Biotech, INC. | $578.20 | 2021-2025 | Erleada, Darzalex, Rybrevant |
| Merck Sharp & Dohme LLC | $576.12 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $342.25 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Pfizer INC. | $307.68 | 2019-2025 | |
| Lilly USA, LLC | $298.85 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
| Exelixis INC. | $283.68 | 2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $274.02 | 2020-2025 | Opdivo |
| Amgen INC. | $253.36 | 2019-2023 | Xgeva, Nplate |
| Seagen INC. | $247.03 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Astellas Pharma US INC | $224.56 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Foundation Medicine, INC. | $222.15 | 2023 | |
| Daiichi Sankyo INC. | $188.94 | 2021-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $188.78 | 2021-2025 | Ojjaara, Zejula, Jemperli |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shajadi Patan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.